Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence.

Roberto Spoladore, Martin S. Maron, Rossella D'Amato, Paolo G. Camici, Iacopo Olivotto

Research output: Contribution to journalArticlepeer-review

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease, affecting over one million individuals in Europe. Hypertrophic cardiomyopathy patients often require pharmacological intervention for control of symptoms, dynamic left ventricular outflow obstruction, supraventricular and ventricular arrhythmias, and microvascular ischaemia. Current treatment strategies in HCM are predicated on the empirical use of long-standing drugs, such as beta-adrenergic and calcium blockers, although with little evidence supporting their clinical benefit in this disease. In the six decades since the original description of the disease,

Original languageEnglish
Pages (from-to)1724-1733
Number of pages10
JournalEuropean Heart Journal
Volume33
Issue number14
DOIs
Publication statusPublished - Jul 2012

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence.'. Together they form a unique fingerprint.

Cite this